Clinical Pharmacokinetics

, Volume 45, Issue 10, pp 1013–1034 | Cite as

Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children

  • Andrea N. EdgintonEmail author
  • Walter Schmitt
  • Stefan Willmann
Original Research Article



Clinical trials in children are being encouraged by regulatory authorities in light of the immense off-label and unlicensed use of drugs in the paediatric population. The use of in silico techniques for pharmacokinetic prediction will aid in the development of paediatric clinical trials by guiding dosing regimens, ensuring efficient blood sampling times, maximising therapeutic effect and potentially reducing the number of children required for the study. The goal of this study was to extend an existing physiologically based pharmacokinetic (PBPK) model for adults to reflect the age-related physiological changes in children from birth to 18 years of age and, in conjunction with a previously developed age-specific clearance model, to evaluate the accuracy of the paediatric PBPK model to predict paediatric plasma profiles.


The age-dependence of bodyweight, height, organ weights, blood flows, interstitial space and vascular space were taken from the literature. Physiological parameters that were used in the PBPK model were checked against literature values to ensure consistency. These included cardiac output, portal vein flow, extracellular water, total body water, lipid and protein. Five model compounds (paracetamol [acetaminophen], alfentanil, morphine, theophylline and levofloxacin) were then examined by gathering the plasma concentration-time profiles, volumes of distribution and elimination half-lives from different ages of children and adults. First, the adult data were used to ensure accurate prediction of pharmacokinetic profiles. The model was then scaled to the specific age of children in the study, including the scaling of clearance, and the generated plasma concentration profiles, volumes of distribution and elimination half-lives were compared with literature values.


Physiological scaling produced highly age-dependent cardiac output, portal vein flow, extracellular water, total body water, lipid and protein values that well represented literature data. The pharmacokinetic profiles in children for the five compounds were well predicted and the trends associated with age were evident. Thus, young neonates had plasma concentrations greater than the adults and older children had concentrations less than the adults. Eighty-three percent, 97% and 87% of the predicted plasma concentrations, volumes of distribution and elimination half-lives, respectively, were within 50% of the study reported values. There was no age-dependent bias for term neonates to 18 years of age when examining volumes of distribution and elimination half-lives.


This study suggests that the developed paediatric PBPK model can be used to scale pharmacokinetics from adults. The accurate prediction of pharmacokinetic parameters in children will aid in the development of dosing regimens and sampling times, thus increasing the efficiency of paediatric clinical trials.


Levofloxacin Alfentanil PBPK Model Total Body Water Term Neonate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No specific funding was received for this project. All authors are employed by Bayer Technology Services (BTS) GmbH.


  1. 1.
    Best Pharmaceuticals for Children Act, January 4, 2002 (Public Law No. 107–109). USA 2005Google Scholar
  2. 2.
    Roberts R, Rodriguez W, Murphy D, et al. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA 2003; 290(7): 905–11PubMedCrossRefGoogle Scholar
  3. 3.
    Choonara I. Unlicensed and off-label drug use in children: implications for safety. Expert Opin Drug Saf 2004; 3(2): 81–3PubMedCrossRefGoogle Scholar
  4. 4.
    Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 2000; 320(7227): 79–82PubMedCrossRefGoogle Scholar
  5. 5.
    Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 2002; 54(6): 665–70PubMedCrossRefGoogle Scholar
  6. 6.
    Turner S, Nunn AJ, Fielding K, et al. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999; 88(9): 965–8PubMedCrossRefGoogle Scholar
  7. 7.
    Kauffman RE, Kearns GL. Pharmacokinetic studies in paediatric patients: clinical and ethical considerations. Clin Pharmacokinet 1992; 23(1): 10–29PubMedCrossRefGoogle Scholar
  8. 8.
    Gobburu JV, Marroum PJ. Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making. Clin Pharmacokinet 2001; 40(12): 883–92PubMedCrossRefGoogle Scholar
  9. 9.
    Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J 2005; 7(3): E503–12PubMedCrossRefGoogle Scholar
  10. 10.
    Nestorov I. Whole body pharmacokinetic models. Clin Pharmacokinet 2003; 42(10): 883–908PubMedCrossRefGoogle Scholar
  11. 11.
    Alcorn J, McNamara PJ. Pharmacokinetics in the newborn. Adv Drug Deliv Rev 2003; 55(5): 667–86PubMedCrossRefGoogle Scholar
  12. 12.
    Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet 2002; 41(12): 959–98PubMedCrossRefGoogle Scholar
  13. 13.
    Ginsberg G, Hattis D, Miller RM, et al. Pediatric pharmacokinetic data: implications for environmental risk assessment for children. Pediatrics 2004; 113(4): 973–83PubMedGoogle Scholar
  14. 14.
    Edginton AN, Schmitt W, Voith B, et al. A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet 2006; 45(7): 683–704PubMedCrossRefGoogle Scholar
  15. 15.
    Johnson TN. Modelling approaches to dose estimation in children. Br J Clin Pharmacol 2005; 59(6): 663–9PubMedCrossRefGoogle Scholar
  16. 16.
    Bjorkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 2005; 59(6): 691–704PubMedCrossRefGoogle Scholar
  17. 17.
    Ginsberg G, Hattis D, Russ A, et al. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children’s risks from environmental agents. J Toxicol Environ Health A 2004; 67(4): 297–329PubMedCrossRefGoogle Scholar
  18. 18.
    Willmann S, Lippert J, Schmitt W. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opin Drug Metab Toxicol 2005; 1(1): 159–68PubMedCrossRefGoogle Scholar
  19. 19.
    Willmann S, Lippert J, Sevestre M, et al. PK-Sim®: a physiologically based pharmacokinetic ‘whole-body’ model. Biosilico 2003; 1(4): 121–4CrossRefGoogle Scholar
  20. 20.
    PK-Sim® software manual [online]. Available from URL: [Accessed 2006 August 21]
  21. 21.
    Syracuse Research Corporation. SRC PhysProp database [online]. Available from URL: [Accessed 2005 Aug 10]
  22. 22.
    Bailey DN, Briggs JR. The binding of selected therapeutic drugs to human serum [alpha]-1 acid glycoprotein and to human serum albumin in vitro. Ther Drug Monit 2004; 26(1): 40–3PubMedCrossRefGoogle Scholar
  23. 23.
    Hardman JG, Limbird LE, Gilman A. Goodman and Gilman’s: the pharmacological basis of therapeutics. 10th ed. New York: McGraw Hill, 2001Google Scholar
  24. 24.
    Roure P, Jean N, Leclerc AC, et al. Pharmacokinetics of alfentanil in children undergoing surgery. Br J Anaesth 1987; 59(11): 1437–40PubMedCrossRefGoogle Scholar
  25. 25.
    Macfie AG, Magides AD, Reilly CS. Disposition of alfentanil in burns patients. Br J Anaesth 1992; 69(5): 447–50PubMedCrossRefGoogle Scholar
  26. 26.
    Kart T, Christrup LL, Rasmussen M. Recommended use of morphine in neonates, infants and children based on a literature review: Part 1 — pharmacokinetics. Paediatr Anaesth 1997; 7(1): 5–11PubMedCrossRefGoogle Scholar
  27. 27.
    Valko K, Nunhuck S, Bevan C, et al. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. J Pharm Sci 2003; 92(11): 2236–48PubMedCrossRefGoogle Scholar
  28. 28.
    Dobashi A. Levofloxacin. Department of Pharmaceutical Information Science, Tokyo University of Pharmacy and Life Science [online]. Available from URL: [Accessed 2005 Aug 23]
  29. 29.
    Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32(2): 101–19PubMedCrossRefGoogle Scholar
  30. 30.
    International Commission on Radiological Protection (ICRP). Basic anatomical and physiological data for use in radiological protection: reference values. ICRP publication 89. Amsterdam: Elsevier Science, 2002Google Scholar
  31. 31.
    Segel SA, Fanelli CG, Dence CS, et al. Blood-to-brain glucose transport, cerebral glucose metabolism, and cerebral blood flow are not increased after hypoglycemia. Diabetes 2001; 50(8): 1911–7PubMedCrossRefGoogle Scholar
  32. 32.
    Epstein HT. Stages of increased cerebral blood flow accompany stages of rapid brain growth. Brain Dev 1999; 21(8): 535–9PubMedCrossRefGoogle Scholar
  33. 33.
    Raynaud C, Chiron C, Maziere B, et al. Followup of regional CBF in children from birth to 18 years with Xe-133 [abstract]. J Nucl Med 1990; 31S: 892Google Scholar
  34. 34.
    Wintermark M, Lepori D, Cotting J, et al. Brain perfusion in children: evolution with age assessed by quantitative perfusion computed tomography. Pediatrics 2004; 113(6): 1642–52PubMedCrossRefGoogle Scholar
  35. 35.
    Visser MOJM, Leighton JO, van de Bor M, et al. Renal blood flow in neonates: quantification with color flow and pulsed doppler US. Radiology 1992; 183(2): 441–4PubMedGoogle Scholar
  36. 36.
    Scholbach T. Color doppler sonographic determination of renal blood flow in healthy children. J Ultrasound Med 1999; 18(8): 559–64PubMedGoogle Scholar
  37. 37.
    Scholbach T. Changes of renal blood flow volume in the hemolytic-uremic syndrome-color Doppler sonographic investigations. Pediatr Nephrol 2001; 16(8): 644–7PubMedCrossRefGoogle Scholar
  38. 38.
    Raitakari M, Nuutila P, Ruotsalainen U, et al. Evidence for dissociation of insulin stimulation of blood flow and glucose uptake in human skeletal muscle: studies using [15O]H2O, [18F]fluoro-2-deoxy-D-glucose, and positron emission tomography. Diabetes 1996; 45(11): 1471–7PubMedCrossRefGoogle Scholar
  39. 39.
    Skovranek J, Samanek M. Chronic impairment of leg muscle blood flow following cardiac catheterization in childhood. AJR Am J Roentgenol 1979; 132(1): 71–5PubMedGoogle Scholar
  40. 40.
    Wu PYK, Wong WH, Guerra G, et al. Peripheral blood flow in the neonate: 1. changes in total, skin, and muscle blood flow with gestational and postnatal age. Pediatr Res 1980; 14(12): 1374–8PubMedCrossRefGoogle Scholar
  41. 41.
    Goetzova J, Skovranek J, Samanek M. Muscle blood flow in children, measured by 133Xe clearance method. Cor Vasa 1977; 19(2): 161–4PubMedGoogle Scholar
  42. 42.
    Mikasa H, Sakuragi T, Higa K, et al. Skin blood flow and plasma catecholamine concentrations during removal of a phaeochromocytoma in a child. Br J Anaesth 2004; 92(5): 757–60PubMedCrossRefGoogle Scholar
  43. 43.
    Chimoskey JE. Skin blood flow by 133Xe disappearance validated be venous occlusion plethysmography. J Appl Physiol 1972; 32(3): 432–4PubMedGoogle Scholar
  44. 44.
    Irazuzta JE, Berde CB, Sethna NF. Laser Doppler measurements of skin blood flow before, during, and after lumbar sympathetic blockade in children and young adults with reflex sympathetic dystrophy syndrome. J Clin Monit 1992; 8(1): 16–9PubMedCrossRefGoogle Scholar
  45. 45.
    Moustogiannis AN, Raju TN, Roohey T, et al. Intravenous morphine attenuates pain induced changes in skin blood flow in newborn infants. Neurol Res 1996; 18(5): 440–4PubMedGoogle Scholar
  46. 46.
    Leggett RW, Williams LR. A proposed blood circulation model for reference man. Health Phys 1995; 69(2): 187–201PubMedCrossRefGoogle Scholar
  47. 47.
    Kagimoto S, Fujitsuka S, Kinoshita K, et al. Study to establish normal values for portal vein blood flow in children using a duplex ultrasound system. Acta Paediatr Jpn 1991; 33(6): 693–6PubMedCrossRefGoogle Scholar
  48. 48.
    Lopez Barrio AM, De Palma Gaston MA, Munoz Conde J. Evaluation of the portal blood flow in healthy children by doppler duplex echography. An Esp Pediatr 1996; 44(1): 45–9Google Scholar
  49. 49.
    Greenway CV, Stark RD. Hepatic vascular bed. Physiol Rev 1971; 51(1): 23–5PubMedGoogle Scholar
  50. 50.
    Winso O, Biber B, Gustavsson B, et al. Portal blood flow in man during graded positive end-expiratory pressure ventilation. Intensive Care Med 1985; 12(2): 80–8Google Scholar
  51. 51.
    Chang AC, Atz AM, Wernovsky G, et al. Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery. Crit Care Med 1995; 23(11): 1907–14PubMedCrossRefGoogle Scholar
  52. 52.
    Sholler GF, Celermajer JM, Whight CM, et al. Echo Doppler assessment of cardiac output and its relation to growth in normal infants [published erratum appears in Am J Cardiol 1988; 61 (10): 872]. Am J Cardiol 1987; 60(13): 1112–9PubMedCrossRefGoogle Scholar
  53. 53.
    Cecchetti C, Stoppa F, Vanacore N, et al. Monitoring of intrathoracic volemia and cardiac output in critically ill children. Minerva Anestesiol 2003; 69(12): 907–18PubMedGoogle Scholar
  54. 54.
    Shekerdemian LS, Bush A, Lincoln C, et al. Cardiopulmonary interactions in healthy children and children after simple cardiac surgery: the effects of positive and negative pressure ventilation. Heart 1997; 78(6): 587–93PubMedGoogle Scholar
  55. 55.
    Pastore E, Turchetta A, Attias L, et al. Cardiorespiratory functional assessment after pediatric heart transplantation. Pediatr Transplant 2001; 5(6): 425–9PubMedCrossRefGoogle Scholar
  56. 56.
    Pianosi PT. Measurement of exercise cardiac output by thoracic impedance in healthy children. Eur J Appl Physiol 2004; 92(4–5): 425–30PubMedGoogle Scholar
  57. 57.
    Kardos A, Vereczkey G, Pirot L, et al. Use of impedance cardiography to monitor haemodynamic changes during laparoscopy in children. Paediatr Anaesth 2001; 11(2): 175–9PubMedCrossRefGoogle Scholar
  58. 58.
    Hjortdal VE, Emmersten K, Stenbog E, et al. Effects of exercise and respiration on blood flow in total cavopulmonary connection: a real-time magnetic resonance flow study. Circulation 2003; 108(10): 1227–31PubMedCrossRefGoogle Scholar
  59. 59.
    Kawai R, Lemaire M, Steimer J, et al. Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J Pharmacokinet Biopharm 1994; 22(5): 327–3PubMedGoogle Scholar
  60. 60.
    Tsuji A, Yoshikawa T, Nishide K, et al. Physiologically based pharmacokinetic model for beta-lactam antibiotics I: tissue distribution and elimination in rats. J Pharm Sci 1983; 72(11): 1239–52PubMedCrossRefGoogle Scholar
  61. 61.
    Baker GL. Human adipose tissue composition and age. Am J Clin Nutr 1969; 22(7): 829–35PubMedGoogle Scholar
  62. 62.
    Dickerson JWT, Widdowson EM. Chemical changes in skeletal muscle during development. Biochemistry 1960; 74: 247–57Google Scholar
  63. 63.
    Levitt DG. The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol 2003; 3: 3PubMedCrossRefGoogle Scholar
  64. 64.
    Boulton TJ, Dunlop M, Court JM. The growth and development of fat cells in infancy. Pediatr Res 1978; 12(9): 908–9PubMedCrossRefGoogle Scholar
  65. 65.
    DeJongh J, Verhaar HJ, Hermens JL. A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans. Arch Toxicol 1997; 72(1): 17–25PubMedCrossRefGoogle Scholar
  66. 66.
    Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 2001; 91(1): 129–56CrossRefGoogle Scholar
  67. 67.
    Friss-Hansen B. Water distribution in the foetus and newborn infant. Acta Paediatr Scand 1983; 305(S): 1–7Google Scholar
  68. 68.
    Battistini N, Virgili F, Severi S, et al. Relative expansion of extracellular water in obese vs. normal children. J Appl Physiol 1995; 79(1): 94–6PubMedGoogle Scholar
  69. 69.
    Hamadeh MJ, Robitaille L, Boismenu D, et al. Human extracellular water volume can be measured using the stable isotope Na2 34SO4 1, 2. J Nutr 1999; 129: 722–7PubMedGoogle Scholar
  70. 70.
    Haschke F, Fomon SJ, Zeigler EE. Body composition of a nine-year-old reference boy. Pediatr Res 1981; 15(5): 847–9PubMedCrossRefGoogle Scholar
  71. 71.
    Fomon SJ, Haschke F, Ziegler EE, et al. Body composition of reference children from birth to age 10 years. Am J Clin Nutr 1982; 35(5S): 1169–75PubMedGoogle Scholar
  72. 72.
    Norberg A, Sandhagen B, Bratteby LE, et al. Do ethanol and deuterium oxide distribute into the same water space in healthy volunteers? Alcohol Clin Exp Res 2001; 25(10): 1423–30PubMedCrossRefGoogle Scholar
  73. 73.
    Zeigler EE, O’Donnell AM, Nelson SE, et al. Body composition of the reference fetus. Growth 1976; 40(4): 329–41Google Scholar
  74. 74.
    Depre M, van Hecken A, Verbesselt R, et al. Tolerance and pharmacokinetics of propacetamol, a paracetamol formulation for intravenous use. Fundam Clin Pharmacol 1992; 6(6): 259–62PubMedCrossRefGoogle Scholar
  75. 75.
    Bannwarth B, Netter P, Lapicque F, et al. Plasma and cerebrospinal fluid concentrations of paracetamol after a single intravenous dose of propacetamol. Br J Clin Pharmacol 1992; 34(1): 79–81PubMedCrossRefGoogle Scholar
  76. 76.
    Egan TD, Minto CF, Hermann DJ, et al. Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Anesthesiology 1996; 84(4): 821–33PubMedCrossRefGoogle Scholar
  77. 77.
    Kharasch ED, Russell M, Garton K, et al. Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anesthesiology 1997; 87(1): 26–35PubMedCrossRefGoogle Scholar
  78. 78.
    Baillie SP, Bateman DN, Coates PE, et al. Age and the pharmacokinetics of morphine. Age Aging 1989; 18(4): 258–62CrossRefGoogle Scholar
  79. 79.
    Skarke C, Schmidt H, Geisslinger G, et al. Pharmacokinetics of morphine are not altered in subjects with Gilbert’s syndrome. Br J Clin Pharmacol 2003; 56(2): 228–31PubMedCrossRefGoogle Scholar
  80. 80.
    Stringer KA, Mallet J, Clarke M, et al. The effect of three different oral doses of verapamil on the disposition of theophylline. Eur J Clin Pharmacol 1992; 43(1): 35–8PubMedCrossRefGoogle Scholar
  81. 81.
    Gisclon LG, Curtin CR, Fowler CL, et al. Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. J Clin Pharmacol 1997; 37(8): 744–50PubMedGoogle Scholar
  82. 82.
    Chien S, Wells TG, Blumer JL, et al. Levofloxacin pharmacokinetics in children. J Clin Pharmacol 2005; 45(2): 153–60PubMedCrossRefGoogle Scholar
  83. 83.
    McNamara PJ, Alcorn J. Protein binding predictions in infants. AAPS PharmSci 2002; 4(1): E4PubMedCrossRefGoogle Scholar
  84. 84.
    Holford NHG, Hale M, Ko HC, et al., editors. Simulation in drug development: good practices. San Francisco (CA): Center for Drug Development Science, University of California San Francisco, 1999Google Scholar
  85. 85.
    Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9(4): 503–12PubMedGoogle Scholar
  86. 86.
    Boyd E. The growth of the surface area of the human body. Minneapolis: The University of Minnesota Press, 1935Google Scholar
  87. 87.
    Tachibana M, Tanaka M, Masubuchi Y, et al. Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyl-transferase 1A subfamily in human liver microsomes. Drug Metab Dispos 2005; 33(6): 803–11PubMedCrossRefGoogle Scholar
  88. 88.
    de Wildt SN, Kearns GL, Leeder JS, et al. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999; 36(6): 439–52PubMedCrossRefGoogle Scholar
  89. 89.
    Allegaert K, Van der Marel CD, Debeer A, et al. Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. Arch Dis Child Fetal Neonatal Ed 2004; 89(1): F25–8PubMedCrossRefGoogle Scholar
  90. 90.
    Autret E, Dutertre JP, Breteau M, et al. Pharmacokinetics of paracetamol in the neonate and infant after administration of propacetamol chlorhydrate. Dev Pharmacol Ther 1993; 20(3–4): 129–34PubMedGoogle Scholar
  91. 91.
    Granry JC, Rod B, Boccard E, et al. Pharmacokinetics and antipyretic effects of an injectable pro-drug of paracetamol (propacetamol) in children. Paediatr Anaesthesiol 1992; 2: 291–5CrossRefGoogle Scholar
  92. 92.
    Mikkelsen S, Feilberg VL, Chistensen CB, et al. Morphine pharmacokinetics in premature and mature newborn infants. Acta Paediatr 1994; 83(10): 1025–8PubMedCrossRefGoogle Scholar
  93. 93.
    Hain RD, Hardcastle A, Pinkerton CR, et al. Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children. Br J Clin Pharmacol 1999; 48(1): 37–42PubMedCrossRefGoogle Scholar
  94. 94.
    Loughnan PM, Sitar DS, Ogilvie RI, et al. Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. J Pediatr 1976; 88(5): 874–9PubMedCrossRefGoogle Scholar
  95. 95.
    Arnold JD, Hill GN, Sansom LN. A comparison of the pharmacokinetics of theophylline in asthmatic children in the acute episode and in remission. Eur J Clin Pharmacol 1981; 20(6): 443–7PubMedCrossRefGoogle Scholar
  96. 96.
    Ellis EF, Koysooko R, Levy G. Pharmacokinetics of theophylline in children with asthma. Pediatrics 1976; 58(4): 542–7PubMedGoogle Scholar
  97. 97.
    Goresky GV, Koren G, Sabourin MA, et al. The pharmacokinetics of alfentanil in children. Anesthesiology 1987; 67(5): 654–9PubMedCrossRefGoogle Scholar
  98. 98.
    Meistelman C, Saint-Maurice C, Lepaul M, et al. A comparison of alfentanil pharmacokinetics in children and adults. Anesthesiology 1987; 66(1): 13–6PubMedCrossRefGoogle Scholar
  99. 99.
    Marlow N, Weindling AM, Van Peer A, et al. Alfentanil pharmacokinetics in preterm infants. Arch Dis Child 1990; 65(4): 349–51PubMedCrossRefGoogle Scholar
  100. 100.
    Davis PJ, Killian A, Stiller RL, et al. Pharmacokinetics of alfentanil in newborn premature infants and older children. Dev Pharmacol Ther 1989; 13(1): 21–7PubMedGoogle Scholar
  101. 101.
    Killian A, Davis PJ, Stiller RL, et al. Influence of gestational age on pharmacokinetics of alfentanil in neonates Dev Pharmacol Ther 1990; 15(2): 82–5PubMedGoogle Scholar
  102. 102.
    den Hollander JM, Hennis PJ, Burm AG, et al. Alfentanil in infants and children with congenital heart defects. J Cardiothorac Anesth 1998; 2(1): 12–7CrossRefGoogle Scholar
  103. 103.
    Bhat R, Chari G, Gulati A, et al. Pharmacokinetics of a single dose of morphine in preterm infants during the first week of life. J Pediatr 1990; 117(3): 477–81PubMedCrossRefGoogle Scholar
  104. 104.
    Olkkola KT, Maunuksela EL, Korpela R, et al. Kinetics and dynamics of postoperative intravenous morphine in children. Clin Pharmacol Ther 1988; 44(2): 128–36PubMedCrossRefGoogle Scholar
  105. 105.
    Pokela ML, Olkkola KT, Seppala T, et al. Age-related morphine kinetics in infants. Dev Pharmacol Ther 1993; 20(1–2): 26–34PubMedGoogle Scholar
  106. 106.
    Aranda JV, Sitar DS, Parsons WD, et al. Pharmacokinetic aspects of theophylline in premature newborns. N Engl J Med 1976; 295(8): 413–6PubMedCrossRefGoogle Scholar
  107. 107.
    Simons FE, Simons KJ. Pharmacokinetics of theophylline in infancy. J Clin Pharmacol 1978; 18(10): 472–6PubMedGoogle Scholar
  108. 108.
    Vichyanond P, Aranyanark N, Visitsuntorn N, et al. Theophylline pharmacokinetics in Thai children. Asian Pac J Allergy Immunol 1994; 12(2): 137–43PubMedGoogle Scholar
  109. 109.
    Agbaba D, Pokrajac M, Varagic VM, et al. Dependence of the renal excretion of theophylline on its plasma concentrations and urine flow rate in asthmatic children. J Pharmacol 1990; 42(12): 827–30CrossRefGoogle Scholar
  110. 110.
    Pohl HR, van Engelen JG, Wilson J, et al. Risk assessment of chemicals and pharmaceuticals in the pediatric population: a workshop report. Regul Toxicol Pharmacol 2005; 42(1): 83–95PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Andrea N. Edginton
    • 1
    Email author
  • Walter Schmitt
    • 1
  • Stefan Willmann
    • 1
  1. 1.Competence Center Systems BiologyBayer Technology Services GmbHLeverkusenGermany

Personalised recommendations